Journals / E Journal of Cardiovascular Medicine / 2021 / Cilt: 9 - Sayı: 3

Effects of COVID-19 Infection on P-Wave Dispersion, P-Wave Peak Time and Atrial Conduction Times

Pages
143–149
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

That’s why, that group may benefit most from strict electrocardiography follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The relationship between atrial conduction times and paroxysmal atrial fibrillation has been demonstrated in some studies.
📊
Key Findings & Data:There have been case reports showing that coronavirus disease-2019 (COVID-19) infection caused arrhythmic cases including atrial fibrillation.
💡
Conclusion & Impact:That’s why, that group may benefit most from strict electrocardiography follow-up.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: The relationship between atrial conduction times and paroxysmal atrial fibrillation has been demonstrated in some studies. There have been case reports showing that coronavirus disease-2019 (COVID-19) infection caused arrhythmic cases including atrial fibrillation. We investigate the effect of different clinical presentations of COVID-19 infection on these parameters in this study. Materials and Methods: We divided the patients who were infected by COVID-19 into three groups according to computerized tomography and real-time polymerase chain reaction test results. The longest P-wave duration, shortest P-wave durations, P-wave dispersion and P-wave peak duration were calculated in the surface electrocardiography of these patients. Results: Patients with both real-time polymerase chain reaction test positive and pneumonia had the highest P-wave maximum duration (113.08±9.671 ms vs 102.44±7.412 ms. and 99.18±9.292 ms; p=0.000) and the highest P-wave dispersion (53.34±7.705 ms vs 40.58±4.813 ms. and 35.42±4.116 ms; p=0.000) and the longest P-wave peak time (56.79±7.767 ms vs 51.92 ms ±6.443 ms and 50.55±11.63 ms; p=0.008). P-wave dispersion was found longer in patients with real-time polymerase chain reaction test only compared to patients with only pneumonia (40.58±4.813 ms. vs 35.42±4.116 ms; p=0.000). Conclusion: Patients with COVID-19 pneumonia with real-time polymerase chain reaction test positivity have longest P-wave dispersion, P-wave maximum duration and P-wave peak duration. It seems that they have a risk of paroxysmal atrial fibrillation. That’s why, that group may benefit most from strict electrocardiography follow-up.

🔖

Cite This Article

BOYRAZ, B., İBİŞOĞLU, E. (2021). Effects of COVID-19 Infection on P-Wave Dispersion, P-Wave Peak Time and Atrial Conduction Times. E Journal of Cardiovascular Medicine, Cilt: 9 - Sayı: 3, 143–149. https://ajindex.com/articles/413904

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. WHO Coronavirus Disease (Covid-19) Dashboard World.18 JUNE 2020. Avaliable at: https://covid19.who.int (Accessed: 18 JUNE 2020)
  2. Reddy V, Reddy V, Mangat S, Shokr M, Kundumadam S, Laharwani H. Wide complex tachycardia in a COVID-19 patient: What is the mechanism? J Electrocardiol 2020;60:200-2
  3. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020;31:1003-8
  4. Beri A, Kotak K. Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient. HeartRhythm Case Rep 2020;6:367-9
  5. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020;382:e38
  6. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949
  7. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55:105932
  8. Turkish Ministry of Health, General Directorate of Public Health Covid-19 (SARS-CoV-2 Infection) Guidebook. 14 April 2020. Avaliable at: https:// covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf
  9. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol 2020;189:846-7
  10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094-9
  11. Rath B, Niehues P, Leitz P, Eckardt L. Vorhofflimmern bei nichtkardialen Infektionen und Sepsis [Atrial fibrillation in patients with sepsis and noncardiac infections]. Herzschrittmacherther Elektrophysiol 2019;30:256-61
  12. Kochav SM, Coromilas E, Nalbandian A, et al. Cardiac Arrhythmias in COVID-19 Infection. Circ Arrhythm Electrophysiol 2020;13:e008719
  13. Seecheran R, Narayansingh R, Giddings S, et al. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection. J Investig Med High Impact Case Rep 2020;8:2324709620925571
  14. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19- related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 2020;17